StreetAlpha
13F holdings · Q3 2026

Bellevue Group AG

Zurich, V8 · files as Bellevue Group AG
Know the moment Bellevue Group AG filesYou follow Bellevue Group AG An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1674546

Bellevue Group AG reported 154 stocks worth $4.8B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are AMGN (7.5%), GILD (6.7%) and VRTX (6.3%). Compared with Q2 2026, the fund opened new positions in KOD, DMRA and ANRO, added to AMGN, REGN and INSM, trimmed GILD, ARGX and RVMD and sold out of RARE, CLDX and GLUE.

Latest filing: what Bellevue Group AG did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
25 new41 added65 trimmed19 sold outBought about $799M · sold about $708M
New 25
See all 25 →
Added 41
See all 41 →
Trimmed 65
  • SYK−$22.9M−31%
  • UNH−$19.1M−35%
  • IMCR−$15.9M−19%
  • TXG−$15.1M−64%
  • EW−$13.1M−20%
See all 65 →
Sold out 19
  • Nuvalent Inc$130M
  • Crinetics Pharmace$98M
  • RARE$66.2M
  • CLDX$44.7M
  • Galecto Inc$42.1M
See all 19 →

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$4.8B+1.4% vs last quarter
Stocks held15425 new · 19 sold out
Top 5 weight30.6%spread out
Turnover34%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
AMGN
Amgen Inc
$363M7.5%862K+10K (+1%)8 of 8
2
GILD
Gilead Sciences Inc
$321M6.7%2.2M−8,080 (−0%)8 of 8
3
VRTX
Vertex Pharmaceuticals I
$302M6.3%579KNo change8 of 8
4
ARGX
Argenx SE
$279M5.8%291K−10K (−3%)8 of 8
5
REGN
Regeneron Pharmaceutical
$212M4.4%280K+122K (+78%)8 of 8
6
RVMD
Revolution Medicines Inc
$205M4.3%999K−49K (−5%)8 of 8
7
INSM
Insmed Inc
$172M3.6%1.5M+115K (+8%)8 of 8
8
VRDN
Viridian Therapeutics Inc
$146M3.0%7.1M+377K (+6%)4 of 8
9
ORKA
Oruka Therapeutics Inc
$137M2.8%1.6M−16K (−1%)3 of 8
10
BIIB
Biogen Inc
$135M2.8%598K+598K (+176801%)8 of 8
🔒 144 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
NUVALENT INC
$130M1.1M
CRINETICS PHARMACEUTICALS IN
$98M2.6M
RARE
Ultragenyx Pharmaceutical in
$66.2M2M
CLDX
Celldex Therapeutics Inc
$44.7M1.2M
GALECTO INC
$42.1M1.6M

🔒 Free account: see all 19.

Reported value

last 8 quarters
$5.2BQ4 '24
$4.5BQ1 '25
$4.5BQ2 '25
$4.8BQ3 '25
$5.3BQ4 '25
$4.2BQ1 '26
$4.8BQ2 '26
$4.8BQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Bellevue Group AG 13F FAQ

What does Bellevue Group AG own?

Bellevue Group AG reported 154 stocks worth $4.8B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are AMGN (7.5%), GILD (6.7%) and VRTX (6.3%). The table above lists every position in the filing (the top 10 without an account).

What did Bellevue Group AG buy and sell in Q3 2026?

Compared with Q2 2026: 25 new positions, 41 added to, 65 trimmed and 19 sold out. New positions include KOD, DMRA and ANRO. It sold all of RARE, CLDX and GLUE.

When will Bellevue Group AG file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Bellevue Group AG's portfolio worth?

The Q3 2026 filing reports $4.8B in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.